Pharmaceutical - Pharma Rep Focus

Scilex's Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect

Fierce Pharma

SEPTEMBER 3, 2024

Semnur Pharmaceuticals, which is working on a non-opioid prospect for sciatica, has agreed to merge with special purpose acquisition company Denali Capital Acquisition Corp. Semnur Pharmaceuticals is following in its parent company Scilex's footsteps with a special purpose acquisition company (SPAC) merger.

Prospecting

Prospecting Pharmaceutical Specialization

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Fierce Pharma

JANUARY 20, 2023

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban fkansteiner Fri, 01/20/2023 - 15:34

Pharmaceutical

ARS Pharmaceuticals hit with surprise FDA rejection of Neffy, its nasal spray epinephrine alternative

Fierce Pharma

SEPTEMBER 20, 2023

ARS Pharmaceuticals learned that lesson the hard way, as the FDA issued a surprise rejection of its anaphylaxis nasal spray Neffy. Positive FDA advisory committee votes aren’t always a blueprint for approval. Positive FDA advisory committee votes aren’t always a blueprint for approval.

FDA

FDA Pharmaceutical

Delaware's Marlex Pharmaceuticals recalls 2 batches of heart failure drug after labeling mix-up

Fierce Pharma

SEPTEMBER 1, 2023

Marlex Pharmaceuticals of New Castle, Delaware, is recalling two lots of digoxin tablets at the 0.125-mg and 0.25-mg When it comes to heart failure medication, a labeling mix-up can have dire consequences. mg dose, and vice versa.

Pharmaceutical

Pharmaceutical Medical

It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash

Fierce Pharma

OCTOBER 31, 2024

Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potentia | Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potential blockbuster Rezdiffra.

Sales

Sales Pharmaceutical Marketing

Pfizer moves to settle more than 10,000 Zantac cases in state courts: Bloomberg

Fierce Pharma

MAY 8, 2024

Following the lead of French pharmaceutical giant Sanofi, Pfizer has agreed to settle more than 10,000 personal-injury claims from users of heartburn drug Zantac, resolving litigation in several U. state courts, according to Bloomberg.

Leads

Leads Pharmaceutical

Orphan drug market to reach $270B by 2028, led by J&J, Vertex and Roche: Evaluate

Fierce Pharma

APRIL 23, 2024

The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales.

Marketing

Marketing Sales Pharmaceutical

Otsuka pulls plug on Alzheimer's agitation drug after 2nd failed trial

Fierce Pharma

MAY 22, 2024

Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on m | Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on measures of agitation associated with dementia.

Pharmaceutical

J&J and Roche are the strongest companies in the biopharma industry, says S&P Global

Fierce Pharma

AUGUST 14, 2024

Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers. | Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers.

Biopharma

Biopharma Pharmaceutical

Teva weighs sale of $2B API business as CEO Richard Francis embarks on 'Pivot to Growth' strategy: reports

Fierce Pharma

JULY 6, 2023

Less than two months into its "Pivot to Growth" strategy under a new CEO, Israeli-American generics giant Teva Pharmaceutical could be weighing a major shake-up of its key drug ingredients business | Teva is looking at strategic options for its active pharmaceutical ingredient unit, with a potential sale on the table, BNN Bloomberg and Benzinga (..)

Sales

Sales Pharmaceutical

Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease

Fierce Pharma

OCTOBER 28, 2024

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy.

Pharmaceutical

Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche's Tecentriq

Fierce Pharma

OCTOBER 15, 2024

Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer (ES- | Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives (..)

Pharmaceutical

Pharmaceutical Marketing Patients

Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia

Fierce Pharma

JANUARY 16, 2024

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FD | Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval came more than two months ahead of the FDA's March 30 decision date.

FDA

FDA Pharmaceutical

Vertex clinches Trikafta and other cystic fibrosis drug reimbursement deal in England

Fierce Pharma

JUNE 21, 2024

Cystic fibrosis (CF) patients and their families in England can rest a little easier this week, thanks to an extended long-term reimbursement deal inked by Vertex Pharmaceuticals and the country’s | Cystic fibrosis (CF) patients and their families in England can rest a little easier this week, thanks to an extended long-term reimbursement deal inked (..)

Pharmaceutical

Pharmaceutical Patients

Alnylam CEO touts 'big-win scenario' for Amvuttra in closely watched heart disease trial

Fierce Pharma

JUNE 24, 2024

In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events in patient | In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death (..)

Pharmaceutical

Pharmaceutical Patients

Vanda, despite FDA rejection, swats down another buyout bid from Cycle

Fierce Pharma

OCTOBER 14, 2024

The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based based company. |

FDA

FDA Pharmaceutical Pharma

Amneal agrees to $272.5M settlement to resolve opioid lawsuits

Fierce Pharma

MAY 6, 2024

Amneal Pharmaceuticals has agreed to pay $272.5 million to settle approximately 900 lawsuits brought by state, local and Native American jurisdictions claiming that the New Jersey generics producer | Amneal Pharmaceuticals has agreed to pay $272.5

Pharmaceutical

As Vertex and CRISPR build out Casgevy launch, doctor sees strong demand and warns of possible supply hitches

Fierce Pharma

DECEMBER 21, 2023

As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their CRISPR-based gene-editing therapy Casgevy, one doctor who treats sickle cell disease patients is already | As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their world-first CRISPR-based gene therapy Casgevy, one doctor (..)

Doctors

Doctors Pharmaceutical Patients

House lawmaker brings FDA into biosecurity crackdown on China

Fierce Pharma

MAY 8, 2024

the House Committee on Oversight and Accountability chairman argued that China’s influence over global pharmaceutical supply chains constitutes an act of economic warfare against the United States. Amid a U.S. | In a letter to FDA Commissioner Robert Califf, M.D.,

FDA

FDA Pharmaceutical

AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players

Fierce Pharma

NOVEMBER 22, 2023

In a lawsuit filed in Delaware federal court Monday, AbbVie accused Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals and Sun Pharmaceutical of trying to sidestep dozens of patents protecting Rinvoq through the next decade.

Pharmaceutical

Pharmaceutical Pharma Marketing

More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce

Fierce Pharma

NOVEMBER 7, 2024

After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring.

Pharmaceutical

US Supreme Court rejects Vanda's bid to revive patents on sleep disorder drug Hetlioz

Fierce Pharma

APRIL 22, 2024

The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S. | The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S.

Prospecting

Prospecting Pharmaceutical

A closer look at 'friend-shoring' and the drug shortage challenge

Fierce Pharma

JUNE 21, 2024

In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing.<

Manufacturing

Manufacturing Pharmaceutical

Bain Capital eyes potential €1B sale of Dutch antibiotics manufacturer Centrient: report

Fierce Pharma

JANUARY 4, 2024

Investment giant Bain Capital is weighing a potential sale of its Dutch antibiotics and active pharmaceutical ingredients (API) specialist Centrient Pharmaceuticals, which could be valued as high as €1 billion ($1.09 billion), Bloomberg reported Wednesday, citing people close to the talks.

Manufacturing

Manufacturing Sales Pharmaceutical

The Evolution of Innovation: Realizing the Therapeutic Benefits of Cannabinoids

Fierce Pharma

OCTOBER 18, 2023

EVP, Global Head of Research and Development at Jazz Pharmaceuticals | Learn more about how Jazz Pharmaceuticals harnesses the therapeutic potential of cannabinoids to drive patient-centric innovation By Robert Iannone, M.D.,

Pharmaceutical

Pharmaceutical Patients

After buying Novan's assets, Ligand crosses FDA finish line with molluscum gel Zelsuvmi

Fierce Pharma

JANUARY 7, 2024

Less than six months after Ligand Pharmaceuticals swooped in to buy Novan’s assets following the latter company’s bankruptcy, the purchase has paid off with an FDA approval. | Less than six months after Ligand Pharmaceuticals swooped in to buy Novan’s assets following the latter company’s bankruptcy, the purchase has paid off with an FDA approval. (..)

FDA

FDA Pharmaceutical

Citius notches first FDA approval, scoring with Lymphir for cutaneous T-cell lymphoma

Fierce Pharma

AUGUST 8, 2024

A year after it was hit with a rejection from the FDA, Citius Pharmaceuticals has scored an approval for Lymphir to treat cutaneous T-Cell Lymphoma.

FDA

FDA Pharmaceutical

European Pharmaceutical Review Issue 5 2024

European Pharmaceutical Review

NOVEMBER 21, 2024

The post <em>European Pharmaceutical Review </em> Issue 5 2024 appeared first on European Pharmaceutical Review. Register your details to access this exclusive content!

Pharmaceutical

Pharmaceutical Consulting Manufacturing

JPM24, Day 3: Alkermes enters new phase after busy year

Fierce Pharma

JANUARY 3, 2024

Morgan Healthcare Conference, attendees will get a chance to hear from AbbVie, Amarin and several other pharmaceutical companies. Morgan Healthcare Conference moves into its third day, we're covering the latest developments here. | On Wednesday at the the J.P.

Healthcare

Healthcare Healthcare Pharmaceutical

After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME

Fierce Pharma

OCTOBER 28, 2024

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in seve | EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising."

Leads

Leads Pharmaceutical

After 17-year courtship, Sun and Taro finally agree on $348M buyout

Fierce Pharma

JANUARY 18, 2024

It took 17 years for Sun Pharmaceutical and Taro Pharmaceutical to finally tie the knot. | It took 17 years for Sun Pharmaceutical and Taro Pharmaceutical to finally tie the knot. The deal nets out to $348 million for a 48% premium on Taro's share price of $29.

Pharmaceutical

JPM24: Johnson & Johnson CEO says Tecvayli, Talvey and several other meds are set to trounce analyst estimates

Fierce Pharma

JANUARY 8, 2024

Johnson & Johnson is starting the year with a new corporate identi | Despite all the recent changes at Johnson & Johnson, the company maintains an aggressive outlook for its pharmaceuticals division. In fact, J&J's sales forecasts for some drugs come in vastly higher than analyst numbers.

Sales

Sales Pharmaceutical

In wake of Reata buyout, Biogen's key launch Skyclarys passes muster in EU

Fierce Pharma

FEBRUARY 12, 2024

billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starti | Roughly half a year after Biogen’s $7.3 Roughly half a year after Biogen’s $7.3

Pharmaceutical

Johnson & Johnson accuses former employee of taking thousands of files to new role at Pfizer

Fierce Pharma

MARCH 20, 2024

As two of the world’s largest pharmaceutical companies, Johnson & Johnson and Pfizer have long been rivals in various therapeutic areas. | The company is accusing former employee Andrew Brackbill of downloading thousands of confidential strategy-related files before leaving for rival Pfizer.

Pharmaceutical

Lexicon to lay off 50% of field force as it prioritizes heart failure drug, potential US diabetes launch

Fierce Pharma

AUGUST 13, 2024

Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it | As part of a restructuring initiative, Lexicon Pharmaceuticals will lay off more than 75 staffers, or approximately 50% of its current field force, by (..)

Prospecting

Prospecting FDA Pharmaceutical

Amid FTC crackdown, judge says Teva inhaler patents are 'improperly listed' in FDA Orange Book

Fierce Pharma

JUNE 12, 2024

The ruling came in Teva's case against Amneal Pharmaceuticals, which is seeking to launch a generic version of the drug. . | A federal judge in New Jersey ruled that five of Teva’s patents on the metered dose inhaler for its asthma med ProAir HFA are “improperly listed” in the FDA’s Orange Book.

FDA

FDA Pharmaceutical

Elevar commits $600M+ to take Hengrui's liver cancer cocktail to market in US and beyond

Fierce Pharma

OCTOBER 17, 2023

As Elevar Therapeutics and Hengrui Pharmaceuticals await an FDA decision on their combination therapy for newly diagnosed unresectable liver cancer—approved in China back in February—the partners a | As Elevar Therapeutics and Hengrui Pharmaceuticals await an FDA decision on their combination therapy for newly-diagnosed unresectable liver cancer—approved (..)

Marketing

Marketing FDA Pharmaceutical

Vanda secures FDA approval for Fanapt to treat bipolar I, 15 years after schizophrenia nod

Fierce Pharma

APRIL 3, 2024

Fifteen years after gaining its first FDA approval for Fanapt (iloperidone) to treat schizophrenia, Vanda Pharmaceuticals has scored again with the same antipsychotic drug. The FDA has signed off on Fanapt tablets to treat adults with manic or mixed episodes associated with bipolar I disorder.

FDA

FDA Pharmaceutical

Pfizer's cost-cutting campaign hits Sandwich site in UK, where 500 workers will lose jobs

Fierce Pharma

NOVEMBER 14, 2023

Pfizer plans to cut approximately 500 roles and ax its Pharmaceutical Sciences Small Molecule capabilities at its site in Sandwich in Kent in the U.K. Earlier this month, Pfizer’s $3.5 billion cost-cutting campaign crossed overseas to Ireland. Now, just a week later, Pfizer is announcing hundreds more job cuts in the U.K.

Pharmaceutical

Amgen expands pact with Amazon to usher drug manufacturing into the AI era

Fierce Pharma

NOVEMBER 29, 2023

. | Amgen is growing its decade-old collaboration with Amazon Web Services—a widely used cloud platform—to create generative artificial intelligence that the companies aim to use to increase the manufacturing throughput of pharmaceuticals.

Manufacturing

Manufacturing Medicine Pharmaceutical

'The Top Line': Breaking down Eli Lilly’s ESG formula

Fierce Pharma

FEBRUARY 23, 2024

This week on “The Top Line,” we explore the impact of environmental, social and governance measures, commonly known as ESG, on the pharmaceutical industry. | This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry.

Government

Government Pharmaceutical Pharma

Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy

Fierce Pharma

SEPTEMBER 24, 2024

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply chain. Vertex has inked a long-term supply agreement with Swiss CDMO Lonza to crank out global commercial supply of Casgevy.

Manufacturing

Manufacturing Pharmaceutical

Proposed chemical ban would cause EU drug manufacturing to 'grind to a halt,' trade group warns

Fierce Pharma

SEPTEMBER 29, 2023

A proposed restriction on the use of fluorinated substances in Europe would have an “irredeemable impact” on the continent’s life sciences sector, the European Federation of Pharmaceutical Industri | A proposed restriction on the use of fluorinated substances in Europe would have an “irredeemable impact” on the continent’s life sciences sector, the (..)

Manufacturing

Manufacturing Pharmaceutical

As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growth

Fierce Pharma

DECEMBER 5, 2023

As Johnson & Johnson places a magnifying glass on its pharmaceutical business, the focus for the remainder of the decade rests on the shoulders of some 25 new and upcoming drugs.

Sales

Sales Pharmaceutical

Scilex's Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Trending Sources

ARS Pharmaceuticals hit with surprise FDA rejection of Neffy, its nasal spray epinephrine alternative

Delaware's Marlex Pharmaceuticals recalls 2 batches of heart failure drug after labeling mix-up

It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash

Pfizer moves to settle more than 10,000 Zantac cases in state courts: Bloomberg

Orphan drug market to reach $270B by 2028, led by J&J, Vertex and Roche: Evaluate

Otsuka pulls plug on Alzheimer's agitation drug after 2nd failed trial

J&J and Roche are the strongest companies in the biopharma industry, says S&P Global

Teva weighs sale of $2B API business as CEO Richard Francis embarks on 'Pivot to Growth' strategy: reports

Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease

Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche's Tecentriq

Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia

Vertex clinches Trikafta and other cystic fibrosis drug reimbursement deal in England

Alnylam CEO touts 'big-win scenario' for Amvuttra in closely watched heart disease trial

Vanda, despite FDA rejection, swats down another buyout bid from Cycle

Amneal agrees to $272.5M settlement to resolve opioid lawsuits

As Vertex and CRISPR build out Casgevy launch, doctor sees strong demand and warns of possible supply hitches

House lawmaker brings FDA into biosecurity crackdown on China

AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players

More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce

US Supreme Court rejects Vanda's bid to revive patents on sleep disorder drug Hetlioz

A closer look at 'friend-shoring' and the drug shortage challenge

Bain Capital eyes potential €1B sale of Dutch antibiotics manufacturer Centrient: report

The Evolution of Innovation: Realizing the Therapeutic Benefits of Cannabinoids

After buying Novan's assets, Ligand crosses FDA finish line with molluscum gel Zelsuvmi

Citius notches first FDA approval, scoring with Lymphir for cutaneous T-cell lymphoma

European Pharmaceutical Review Issue 5 2024

JPM24, Day 3: Alkermes enters new phase after busy year

After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME

After 17-year courtship, Sun and Taro finally agree on $348M buyout

JPM24: Johnson & Johnson CEO says Tecvayli, Talvey and several other meds are set to trounce analyst estimates

In wake of Reata buyout, Biogen's key launch Skyclarys passes muster in EU

Johnson & Johnson accuses former employee of taking thousands of files to new role at Pfizer

Lexicon to lay off 50% of field force as it prioritizes heart failure drug, potential US diabetes launch

Amid FTC crackdown, judge says Teva inhaler patents are 'improperly listed' in FDA Orange Book

Elevar commits $600M+ to take Hengrui's liver cancer cocktail to market in US and beyond

Vanda secures FDA approval for Fanapt to treat bipolar I, 15 years after schizophrenia nod

Pfizer's cost-cutting campaign hits Sandwich site in UK, where 500 workers will lose jobs

Amgen expands pact with Amazon to usher drug manufacturing into the AI era

'The Top Line': Breaking down Eli Lilly’s ESG formula

Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy

Proposed chemical ban would cause EU drug manufacturing to 'grind to a halt,' trade group warns

As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growth

Stay Connected